Prognostic value of systemic inflammatory response syndrome after transcatheter aortic valve implantation

Aims Systemic inflammatory response syndrome (SIRS) could affect mortality after transcatheter aortic valve implantation (TAVI) up to 12 months of follow-up. The aim of this study was to evaluate the prevalence of SIRS after TAVI and its impact on all-cause mortality up to 24 months follow-up. Methods We retrospectively enrolled 132 patients with symptomatic severe aortic stenosis undergoing TAVI. SIRS development during the first 72 h after the intervention was evaluated. Other postoperative complications were defined according to the Valve Academic Research Consortium 2 (VARC2). All patients underwent follow-up at 30 days and 24 months. Endpoints were 30-days and 24-months mortality. Results Post-TAVI SIRS developed in 27 patients (20%). At 30-day follow-up, all-cause death occurred in 10 (8%) patients and SIRS occurred more frequently in patients with adverse short-term outcome (60 vs. 17%; P = 0.001). Twenty-four months all-cause death occurred in 25 (19%) patients. SIRS resulted as an independent predictor of long-term outcome [hazard ratio 3.7; 95% confidence interval (95% CI) 1.5–9; P = 0.004], along with major vascular complications (hazard ratio 4; 95% CI 1.6–9.9; P = 0.003), relevant bleedings (hazard ratio 6.4; 95% CI 1.5–28; P = 0.013) and baseline pulmonary hypertension (hazard ratio 2.4; 95% CI 1.05–5.6; P = 0.039). Conclusion Postoperative SIRS was more frequent in patients who died at 30 days follow-up. Moreover, SIRS resulted as a predictor of 24-month mortality along with vascular complications, relevant bleedings and baseline pulmonary hypertension.

[1]  S. Fichtlscherer,et al.  Inflammatory signatures are associated with increased mortality after transfemoral transcatheter aortic valve implantation , 2020, ESC heart failure.

[2]  P. Guida,et al.  Prevalence and Clinical Impact of Systemic Inflammatory Reaction After Cardiac Surgery. , 2019, Journal of cardiothoracic and vascular anesthesia.

[3]  K. Eagle,et al.  Systemic inflammatory response syndromes in the era of interventional cardiology. , 2018, Vascular pharmacology.

[4]  Jeroen J. Bax,et al.  2017 ESC/EACTS Guidelines for the management of valvular heart disease. , 2017, European heart journal.

[5]  Y. Arbel,et al.  Steroid therapy and conduction disturbances after transcatheter aortic valve implantation. , 2016, Cardiovascular therapeutics.

[6]  Christopher W Seymour,et al.  Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[7]  G. Nickenig,et al.  CD-144 positive endothelial microparticles are increased in patients with systemic inflammatory response syndrome after TAVI. , 2016, International journal of cardiology.

[8]  R. Charnigo,et al.  Thromboinflammatory response and predictors of outcomes in patients undergoing transcatheter aortic valve replacement , 2016, Journal of Thrombosis and Thrombolysis.

[9]  K. Swedberg,et al.  2015 ESC Guidelines for the Diagnosis and Management of Pericardial Diseases. , 2015, Revista espanola de cardiologia.

[10]  S. Windecker,et al.  Technical Approach Determines Inflammatory Response after Surgical and Transcatheter Aortic Valve Replacement , 2015, PloS one.

[11]  N. Al-Attar,et al.  2015 ESC Guidelines for the diagnosis and management of pericardial diseases , 2015, European heart journal.

[12]  S. Yusuf,et al.  Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[13]  S. Fichtlscherer,et al.  Occurrence and prognostic impact of systemic inflammatory response syndrome in transfemoral and transapical aortic valve implantation with balloon- and self-expandable valves. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[14]  J. T. ten Berg,et al.  The systemic inflammatory response syndrome predicts short-term outcome after transapical transcatheter aortic valve implantation. , 2015, Journal of cardiothoracic and vascular anesthesia.

[15]  R. Damiano,et al.  Systemic inflammatory response syndrome after transcatheter or surgical aortic valve replacement , 2015, Heart.

[16]  Oktay Korun,et al.  Risk Factors for Systemic Inflammatory Response After Congenital Cardiac Surgery , 2015, Journal of cardiac surgery.

[17]  B. Hoit,et al.  Post-cardiac injury syndromes. An emerging cause of pericardial diseases. , 2013, International journal of cardiology.

[18]  Richard D. White,et al.  American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. , 2013, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[19]  G. Nickenig,et al.  Systemic inflammatory response syndrome predicts increased mortality in patients after transcatheter aortic valve implantation. , 2012, European heart journal.

[20]  G. Nickenig,et al.  Renal function as predictor of mortality in patients after percutaneous transcatheter aortic valve implantation. , 2010, JACC. Cardiovascular interventions.

[21]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[22]  M. Mack,et al.  Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). , 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[23]  J. Caro ESC/EACTS Guidelines on the management of valvular heart disease , 2012 .